Several compounds or new chemical entities (NCEs) from this class lower glucose and improve insulin sensitivity in preclinical models of type 2 diabetes. The patent covers the first NCE that Sirtris plans to take into a human clinical safety trial in the first half of 2008.
Karl Normington, senior director of intellectual property at Sirtris, said: “Sirtris has a strong intellectual property program with over 180 patent applications for broad coverage of sirtuin activators, including composition of matter, formulations, and methods of treatment claims.”